Q3 2024 · 13F-HR
Bain Capital Life Sciences Investors, LLCholdings as filed
Filed 2024-11-14 · accession 0000950123-24-011417
$961.2M
Reported value
24
Positions
2024-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 670703107 | NUVL | NUVALENT INC | $275.9M | 28.7% | 2,697,267 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $173.9M | 18.1% | 10,473,913 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $88.2M | 9.18% | 1,795,735 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $82.5M | 8.58% | 3,013,423 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC | $61.8M | 6.43% | 14,565,457 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $61.2M | 6.36% | 3,303,381 | Common | SOLE |
| 03589W102 | ANNX | ANNEXON INC | $50.0M | 5.20% | 8,449,748 | Common | SOLE |
| 83422E204 | SLDB | SOLID BIOSCIENCES INC | $28.1M | 2.93% | 4,034,582 | Common | SOLE |
| 87583X109 | TNGX | TANGO THERAPEUTICS INC | $20.9M | 2.17% | 2,712,008 | Common | SOLE |
| 501976104 | KYTX | KYVERNA THERAPEUTICS INC | $16.5M | 1.71% | 3,368,370 | Common | SOLE |
| 59045L106 | — | MERSANA THERAPEUTICS INC | $16.4M | 1.70% | 8,663,673 | Common | SOLE |
| 12674W109 | CABA | CABALETTA BIO INC | $13.0M | 1.36% | 2,760,888 | Common | SOLE |
| 98420X103 | ASNSUSD | X4 PHARMACEUTICALS INC | $11.3M | 1.18% | 16,915,784 | Common | SOLE |
| 15673T100 | IPSC | CENTURY THERAPEUTICS INC | $9.3M | 0.96% | 5,410,361 | Common | SOLE |
| 04683R106 | AVIR | ATEA PHARMACEUTICALS INC | $8.3M | 0.87% | 2,485,638 | Common | SOLE |
| 171757206 | CDTX | CIDARA THERAPEUTICS INC | $7.6M | 0.79% | 703,080 | Common | SOLE |
| 75340L104 | RPID | RAPID MICRO BIOSYSTEMS INC | $7.5M | 0.78% | 8,434,560 | Common | SOLE |
| 12529R107 | CCCC | C4 THERAPEUTICS INC | $6.3M | 0.66% | 1,111,910 | Common | SOLE |
| 87184Q206 | SYRS | SYROS PHARMACEUTICALS INC | $5.9M | 0.62% | 2,750,151 | Common | SOLE |
| 63909J108 | NAUT | NAUTILUS BIOTECHNOLOGY INC | $5.7M | 0.59% | 2,000,000 | Common | SOLE |
| 56854Q200 | MRNS* | MARINUS PHARMACEUTICALS INC | $4.7M | 0.49% | 2,693,380 | Common | SOLE |
| 98422T100 | — | XILIO THERAPEUTICS INC | $3.6M | 0.37% | 4,566,817 | Common | SOLE |
| 00534A102 | IVVD | INVIVYD INC | $1.8M | 0.19% | 1,799,595 | Common | SOLE |
| N62509117 | NAMSW | NEWAMSTERDAM PHARMA COMPANY | $700,000 | 0.07% | 100,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.